Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), sold 5,000 shares at $25.00 ($125K) on 2025-11-26, disclosed to the SEC on 2025-11-26.
Scheduled sale ($125k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RCUS | SELL | 2025-12-18 | $557K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |
| RCUS | SELL | 2025-01-03 | $54K | — | Filing → |